Physicians May Underestimate Recurrence of Gastrointestinal Tumors After Resection

Share this content:
For patients with resectable gastrointestinal stromal tumors (GISTs), physicians tend to underestimate risk of recurrence.
For patients with resectable gastrointestinal stromal tumors (GISTs), physicians tend to underestimate risk of recurrence.

For patients with resectable gastrointestinal stromal tumors (GISTs), physicians tend to underestimate risk of recurrence, according to a recent study published online ahead of print in JAMA Oncology.

Annie Guérin of the Analysis Group Inc. in Montreal and fellow researchers conducted a retrospective review of medical records of 506 patients with GISTs after primary resection reported by 109 oncologists in 2013.

Risk of recurrence after complete primary GIST resection was categorized as “underestimated” if oncologist-charted risk assessments of these patients were lower than assessments based on the Revised National Institutes of Health Consensus Criteria.

The researchers found that physicians underestimated risk for 190 patients (37.5%). In addition, 30.1% of tumors with intermediate-level mitotic count and intermediate tumor size (6 to 10 cm) were correctly recognized as high-risk.

RELATED: Long-Term Safety, Efficacy of Sunitinib for Gastrointestinal Tumors Confirmed

A smaller number of high-risk patients that were considered to be underestimated had at least 3 years of planned adjuvant therapy compared to the not-underestimated patients.

Planned adjuvant treatment of at least 3 years compared to less than 3 years in high-risk patients demonstrated a lower hazard of recurrence or death.

Reference

  1. Guérin A, Sasane M, Keir CH, et al. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection. JAMA Oncology. doi:10.1001/jamaoncol.2015.2407. [epub ahead of print]. July 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters